Two Phase 3 Pembrolizumab Trials Show Lack of Benefit in Prostate/Lung CancerMarch 5th 2023
Investigators report that pembrolizumab plus enzalutamide and androgen deprivation therapy does not significantly improve outcomes in castration-resistant prostate cancer; neither did pembrolizumab/chemotherapy in non–small cell lung cancer.
FDA Expands Abemaciclib Approval to Include HR+ HER2– Node+ High-Risk Breast CancerMarch 3rd 2023
Patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer at a high risk of relapse who are eligible for treatment with abemaciclib can be identified via nodal status as well as tumor size and grade.
COVID-19 Vaccination in Patients With Cancer and Recipients of Cellular TherapyMarch 2nd 2023
Fareed Khawaja, MBBS, and colleagues provide a comprehensive overview of COVID-19 vaccine efficacy and safety among patients with cancer in the United States.
FDA Receives NDA for Niraparib/DAT Abiraterone in Prostate Cancer SubtypeMarch 1st 2023
Patients with BRCA-positive metastatic castration-resistant prostate cancer may benefit from treatment with niraparib plus dual action abiraterone acetate tablets and prednisone, a new drug application for which was submitted to the FDA.
Ongoing Trials Aim to Determine Best Regimen for Transplant-Ineligible Patients With MyelomaMarch 1st 2023
Luciano J. Costa, MD, PhD, discussed additional studies evaluating various treatment regimens for transplant-ineligible patients with newly diagnosed multiple myeloma, aiming to determine the best standard in this population.
GRIFFIN Trial Supports Use of Dara-VRd in Transplant-Eligble Patients With MyelomaFebruary 28th 2023
Luciano J. Costa, MD, PhD, discussed the results from the phase 2 GRIFFIN study, designed to evaluate the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in transplant-eligible patients with multiple myeloma.
Mediterranean Diet Correlates With Responses to Melanoma ImmunotherapyFebruary 28th 2023
Previous research has identified a link between nutrients commonly found in a Mediterranean diet such as fiber, unsaturated fats, antioxidants, and polyphenols, and immunomodulatory/anti-tumor activities, according to a dietician from the University of Groningen.
MAIA trial Supports Use of D-Rd in Transplant-Ineligible Patients With MyelomaFebruary 27th 2023
Luciano J. Costa, MD, PhD discussed updating findings from the phase 3 MAIA trial of the triplet combination of daratumumab, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma.
Oncology On-The-Go Podcast: Time to Treatment for Breast Cancer in Rural PopulationsFebruary 27th 2023
Minh-Tri Nguyen, MD, spoke with CancerNetwork® about differences between time to treatment, socioeconomic status, and clinical outcomes in rural and urban patients with breast cancer.
Genomic Analysis Yields ‘Hypothesis Generating’ Data in Bladder Cancer SubtypeFebruary 26th 2023
An expert from Chase Comprehensive Cancer Center discusses how findings from a genomic analysis of the phase 2 BLASST-1 trial may identify biomarkers of response and resistance to nivolumab/chemotherapy in muscle-invasive bladder cancer.